Autolus Therapeutics Limited IPO Research Information

Autolus Therapeutics Limited IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Autolus Therapeutics Limited, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Autolus Therapeutics Limited	AUTL - NASDAQ	$15.00-$17.00	$17.00	$28.00	8.8 million	6/22/2018
Underwriter(s): Goldman Sachs & Co., Jefferies
Co-Manager(s): Wells Fargo Securities, William Blair
Industry: Health Care
Filing(s): Filed 2018-05-07 Terms Added 2018-06-08 Final Prospectus 2018-06-21

Autolus Therapeutics Limited Quote & Chart - Click for current quote - AUTL

About Autolus Therapeutics Limited (adapted from Autolus Therapeutics Limited prospectus):
They are a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "AUTL" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.